Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|4|516-525

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.4, 2018-02, pp. : 516-525

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 1352-0504, Iss. 11, 2015-11 ,pp. : 861-870

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 11, 2015-11 ,pp. : 861-870

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in serum lipid profiles caused by three regimens of interferon‐free direct‐acting antivirals for patients infected with hepatitis C virus

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E203-E212

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon Reduces the Risk of Hepatocellular Carcinoma in Hepatitis C Virus-Related Chronic Hepatitis/Liver Cirrhosis

By  

Oncology, Vol. 78, Iss. 1, 2010-07 ,pp. : 17-23

Karger

Access to resources Recommend Favorite

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 129-134

John Wiley & Sons Inc

Access to resources Recommend Favorite